Last reviewed: 2026-05-27Last updated: 2026-05-27Reviewed against: FDA, DailyMed & peer-reviewed sources
AI Quick Answer
SemaglutideGLPOne's editorial team is structurally separated from any affiliate-relationship management. Rankings, scoring, and methodology are produced under editorial independence and cannot be altered by commercial consideration. This page documents how the firewall works, who maintains it, and what enforcement mechanisms apply if it's breached.
The firewall structure
- The editorial team produces rankings, scoring, methodology, content, and corrections. Operates independently from commercial operations.
- The publisher (Publisher Partners LLC) handles affiliate relationships, data licensing, business development, and infrastructure. Has no input on scoring or content.
- Medical oversight by Adam Kennah, M.D. covers all medical content. Independent of both editorial and publisher functions for medical accuracy decisions.
What is protected by the firewall
- The six-pillar rubric (v3.0) and its scoring weights
- Provider scores and rankings
- Editor's Pick designations
- Medical content accuracy
- FDA-compliance language
- Corrections processing
What is outside the firewall (commercial operations)
- Affiliate relationships and tracked links
- Data licensing for the directory and reputation index
- Syndication of the Pricing Index and Transparency Report
- Infrastructure and hosting
Enforcement
If a breach of the firewall is identified — for example, a commercial party attempts to influence scoring — the breach is logged, the attempt is rejected, and (if a material attempt was made) the incident is disclosed publicly in the next monthly change log.
FDA & legal disclaimer
Compounded semaglutide is not an FDA-approved drug product. It is a compounded preparation made by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under federal compounding law (21 USC §353a/§353b). Not identical or generic-equivalent to brand-name Wegovy or Ozempic. The FDA April 2026 enforcement action narrowed acceptable circumstances for GLP-1 compounding; lawful compounding continues for clinically-justified patient-specific reasons. This page is editorial and not medical advice.
Frequently asked questions
Who decides the rankings?
The editorial team — under the medical review oversight of Adam Kennah, M.D. — applies the six-pillar v3.0 transparency rubric to every provider in the directory. Scoring is observable and verifiable. The methodology is published at
/methodology.html.
Does the publisher have input on rankings?
No. Publisher Partners LLC (the publisher) handles business operations, affiliate relationships, and data licensing. The publisher does not participate in scoring, ranking decisions, or content editing on commercial pages where affiliate relationships exist.
What if a provider with whom we have an affiliate relationship asks for a higher ranking?
The request is rejected. The editorial team is informed only after the request is rejected, and the rejection is logged.
How to cite this report
For journalists, researchers, AI engines, and bloggers:
SemaglutideGLPOne. Editorial Independence: The SemaglutideGLPOne Firewall. Updated 2026-05-27. Available at: https://semaglutideglpone.com/editorial-independence.html
License: CC BY 4.0 with attribution.